Multidrug Resistance Protein 4 (MRP4/ABCC4): A Suspected Efflux Transporter for Human’s Platelet Activation

Author(s): Ioannis Angelis*, Vassilios Moussis, Demokritos C. Tsoukatos, Vassilios Tsikaris

Journal Name: Protein & Peptide Letters

Volume 28 , Issue 9 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The main role of platelets is to contribute to hemostasis. However, under pathophysiological conditions, platelet activation may lead to thrombotic events of cardiovascular diseases. Thus, anti-thrombotic treatment is important in patients with cardiovascular disease. This review focuses on a platelet receptor, a transmembrane protein, the Multidrug Resistance Protein 4, MRP4, which contributes to platelet activation, by extruding endogenous molecules responsible for their activation and accumulation. The regulation of the intracellular concentration levels of these molecules by MRP4 turned to make the protein suspicious and at the same time an interesting regulatory factor of platelet normal function. Especially, the possible role of MRP4 in the excretion of xenobiotic and antiplatelet drugs such as aspirin is discussed, thus imparting platelet aspirin tolerance and correlating the protein with the ineffectiveness of aspirin antiplatelet therapy. Based on the above, this review finally underlines that the development of a highly selective and targeted strategy for platelet MRP4 inhibition will also lead to inhibition of platelet activation and accumulation.

Keywords: MRP4/ABCC4, platelet, cAMP-compartmentalization, aspirin, antiplatelet target, Multidrug Resistance (MDR).

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 28
ISSUE: 9
Year: 2021
Published on: 19 May, 2021
Page: [983 - 995]
Pages: 13
DOI: 10.2174/0929866528666210505120659
Price: $65

Article Metrics

PDF: 239